Novartis P/E Ratio
Current P/E Ratio
45.02
High Valuation
Very High - High growth expectations or significantly overvalued
Novartis (NOVARTIND) P/E ratio is 45.02 (High), EPS (TTM) ₹37.74, current price ₹1641.20 on NSE — Very High - High growth expectations or significantly overvalued. See NOVARTIND P/B ratio history to compare market price against book value per share.
Current Valuation Metrics
P/E Ratio
45.02
Current Price
₹1641.20
EPS (TTM)
₹37.74
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
55.7
Sector Median
31.4
Sector Rank
#11 of 194
Sector Percentile
5.7%
NOVARTIND P/E Ratio — Valuation Signal & Historical Context
Novartis P/E 45.02 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see NOVARTIND screener.
- Stock appears overvalued with PE of 45.02, suggesting caution for new investments
- Trading at discount to sector average PE of 55.7
NOVARTIND vs Healthcare Peers — P/E Ratio Comparison
Novartis P/E 45.02 vs Healthcare average 55.7, median 31.4 — range 2.86–916.67.
Sector Average
55.7
Sector Median
31.4
Lowest P/E
2.86
Highest P/E
916.67
Companies
194
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.61 | ₹64 | Low |
| Sunrest Lifescience | SUNREST | 3.76 | ₹30 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.76 | ₹7,399 | Low |
| Shelter Pharma | SHELTER | 5.23 | ₹47 | Low |
| Dipna Pharmachem | DPL | 5.39 | ₹14 | Low |
| JFL Life Sciences | JFLLIFE | 5.41 | ₹68 | Low |
| Amwill Health Care | AMWILL | 7.26 | ₹83 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹84 | Low |
| Galaxy Medicare | GML | 7.8 | ₹27 | Low |